论文部分内容阅读
应用免疫组化S-P法对20例正常乳腺组织、40例乳腺非典型增生、8例导管原位癌及52例浸润性导管瘤进行ER、PR及CEA检测，探讨乳腺癌发生过程中三者的变化规律。结果：非典型增生、导管原位癌及浸润性导管瘤ER、PR及CEA阳性率显著高于正常组（P＜0．005、P＜0．01），非典型增生与浸润性导管癌CEA表达有非常显著性差异（P＜0．005），其余各组间均无明显差异（P＞025、P＞0．1、P＞05）；各级非典型增生与Ⅰ、Ⅱ级导管癌之间ER、PR及CEA表达无显著性差异（P＞0．5、P＞0．05）。表明非典型增生与导管瘤Ⅰ、Ⅱ级组间细胞生物学特性的近似性，对乳腺癌的早期诊断及预防性治疗有重要临床意义。
Immunohistochemical SP method was used to detect ER, PR and CEA in 20 cases of normal breast tissue, 40 cases of breast atypical hyperplasia, 8 cases of ductal carcinoma in situ, and 52 cases of invasive ductal carcinoma. The law of change. Results: The positive rates of ER, PR and CEA in atypical hyperplasia, ductal carcinoma in situ and invasive ductal carcinoma were significantly higher than those in the normal group (P<0.005, P<0.01). Atypical hyperplasia and invasive ductal carcinoma CEA There was a significant difference in expression (P<0.005). There was no significant difference among the other groups (P>025, P>0.1, P>05); all grades of atypical hyperplasia and grade I and II ductal carcinomas There was no significant difference in the expression of ER, PR and CEA (P>0.5, P>0.05). It shows that the similarity between the atypical hyperplasia and the cell biological characteristics between the I and II groups of ductal tumors has important clinical significance for the early diagnosis and preventive treatment of breast cancer.